In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research Report), with a price target of $7.00. The company’s shares opened today at $1.54.
According to TipRanks, Pantginis is an analyst with an average return of -14.9% and a 30.73% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Ligand Pharma, and Rigel.
Armata Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.46 and a one-year low of $1.28. Currently, Armata Pharmaceuticals has an average volume of 13.23K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Read More on ARMP:
